Chronic Kidney Disease Chronic Renal Failure Market

DelveInsight's "Chronic Kidney Disease (Chronic Renal Failure) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Chronic Kidney Disease (Chronic Renal Failure), historical and forecasted epidemiology as well as the Chronic Kidney Disease (Chronic Renal Failure) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Chronic Kidney Disease (Chronic Renal Failure) market report provides current treatment practices, emerging drugs, Chronic Kidney Disease (Chronic Renal Failure) market share of the individual therapies, current and forecasted Chronic Kidney Disease (Chronic Renal Failure) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Chronic Kidney Disease (Chronic Renal Failure) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.


Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Study Period: 2017-2030


Chronic Kidney Disease (Chronic Renal Failure) Disease Understanding and Treatment Algorithm

Chronic kidney disease (CKD) is a syndrome where there is persistent alterations in kidney structure, function, or both with implications on the health of the individual. Examples of structural abnormalities include cysts, tumors, malformations and atrophy, which are evident on imaging. By contrast, kidney dysfunction can manifest as hypertension, edema, changes in output or quality of urine and growth delay in children, these changes are most often recognized by increased serum levels of creatinine, cystatin C, or blood urea nitrogen. The most common pathological manifestation of CKD, regardless of the initiating insult or disease, is some form of renal fibrosis. 


Several aspects need to be considered when managing patients with CKD, including controlling further nephron injury, normalizing single-nephron hyperfiltration, controlling CKD-related complications and preparing the patient for kidney replacement therapy. Atthe core of these is the principle of ‘the earlier, the better’, which is the effort to reduce the progression to ESRD and optimize renal outcomes. 


The DelveInsight Chronic kidney disease (CKD) market report gives the thorough understanding of the Warm Autoimmune Hemolytic Anemia by including details such as disease definition, classification, symptoms, etiology and risk factors, pathophysiology, disease progression and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Chronic kidney disease.


Chronic Kidney Disease Epidemiology  

The Chronic kidney disease (CKD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.


The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Diagnosed Prevalent cases of CKD, Prevalent cases of CKD by stage, Prevalent cases of CKD by etiologies, Comorbidities associated with CKD, Dialysis dependency in CKD) scenario of Chronic kidney disease (CKD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017–2030.


According to DelveInsight, the total number of prevalent cases of Chronic kidney disease (CKD) in 7 MM was found to be 122,704,658 in the year 2017.


Chronic Kidney Disease Drug Chapters

This segment of the Warm Autoimmune Hemolytic Anemia report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details and the latest news and press releases.


The chronic kidney disease (CKD) drugs market is categorized on the basis of drug class such as Erythropoietin stimulating agents (ESA), Angiotensin-converting-enzyme inhibitors and Angiotensin receptor blockers (ACE-I and ARBs), Antidiabetics, Secondary Hyperparathyroidism Treatment (SHPT), and Urate Lowering Therapies.


Chronic Kidney Disease (Chronic Renal Failure) Market Outlook

The Chronic kidney disease market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. 


This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. 


According to DelveInsight, the market of Chronic kidney disease in 7MM was found to be USD 7,988.1 million in 2017, and is expected to increase during the course of the study period (2017–2030).


Among the 7MM, the United States accounts for the largest market size of CKD, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.


Chronic Kidney Disease (Chronic Renal Failure) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017–2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Chronic Kidney Disease (Chronic Renal Failure) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Chronic Kidney Disease (Chronic Renal Failure) Pipeline Analysis
  • Chronic Kidney Disease (Chronic Renal Failure) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies


Chronic Kidney Disease (Chronic Renal Failure) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage 
  • Chronic Kidney Disease (Chronic Renal Failure) Epidemiology Segmentation
  • Key Cross Competition 
  • Highly Analyzed Market
  • Drugs Uptake


Chronic Kidney Disease (Chronic Renal Failure) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers


Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Chronic kidney disease market
  • Organize sales and marketing efforts by identifying the best opportunities for Chronic kidney disease market
  • To understand the future market competition in the Chronic kidney disease market.



What is Chronic Kidney Disease?

Chronic Kidney Disease (CKD), also known as Chronic Renal Disease, is a condition characterized by a gradual loss of kidney function over time. Because of this, excess fluid and waste from blood remain in the body and may cause other health problems, such as heart disease and stroke.


What are the emerging therapies in the Chronic Kidney Disease pipeline?

Launch of emerging therapies such Roxadustat (Astellas Pharma), Empagliflozin (Boehringer Ingelheim), FG-4592 (FibroGen), veverimer (Tricida), HyPoietin (long-acting EPO, GX-E2) (Genexine) will significantly impact the CKD market during the forecast period (2017-2028).


Which are the leading companies in Chronic Kidney Disease market?

Some of the key players in the therapeutic Chronic Kidney Disease (CKD) market at a global level are Astellas Pharma, Boehringer Ingelheim, Tricida, FibroGen, Genexine, and others.


How is epidemiology segmented for Chronic Kidney Disease?

Chronic Kidney Disease epidemiology is segmented by total prevalent cases, diagnosed and treatable prevalent cases, gender-specific, age-specific, and stage-specific prevalent cases in the 7MM (2017-28).

1. Key Insights

2. Executive Summary of Chronic Kidney Disease

3. SWOT Analysis for Chronic Kidney Disease

4. Chronic Kidney Disease (CKD) Market Overview at a Glance

4.1. Market Share (%) Distribution of Chronic Kidney Disease (CKD) in 2017

4.2. Market Share (%) Distribution of Chronic Kidney Disease (CKD) in 2030

5. Disease Background and Overview

5.1. Introduction

5.2. The KDIGO classification of CKD

5.3. Risk factors associated with CKD

5.4. Signs and symptoms

5.5. Pathophysiology

. Complications

5.6. Disease Progression

5.7. Diagnosis, Screening and Prevention

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Prevalent Patient Population of Chronic Kidney Disease (CKD)

. Country Wise-Epidemiology of CKD

6.3. The United States

6.3.1. Assumptions and Rationale

6.3.2. Diagnosed Prevalent cases of CKD

6.3.3. Prevalent cases of CKD by stage

6.3.4. Prevalent cases of CKD by etiologies in the United States

6.3.5. Comorbidities associated with CKD in the United States

6.3.6. Dialysis Dependency in CKD

6.4. EU-5

6.4.1. Assumptions and Rationale

6.4.2. Germany

6.4.2.1. Diagnosed Prevalent cases of CKD in Germany

6.4.2.2. Prevalent cases of CKD by stage in Germany

6.4.2.3. Prevalent cases of CKD by etiologies in Germany

6.4.2.4. Comorbidities associated with CKD in Germany

6.4.2.5. Dialysis Dependency in CKD in Germany

6.4.3. France

6.4.3.1. Diagnosed Prevalent cases of CKD in France

6.4.3.2. Prevalent cases of CKD by stage in France

6.4.3.3. Prevalent cases of CKD by etiologies in France

6.4.3.4. Comorbidities associated with CKD in France

6.4.3.5. Dialysis Dependency in CKD in France

6.4.4. Italy

6.4.4.1. Diagnosed Prevalent cases of CKD in Italy

6.4.4.2. Prevalent cases of CKD by stage in Italy

6.4.4.3. Prevalent cases of CKD by etiologies in Italy

6.4.4.4. Comorbidities associated with CKD in Italy

6.4.4.5. Dialysis Dependency in CKD in Italy

6.4.5. Spain

6.4.5.1. Diagnosed Prevalent cases of CKD in Spain

6.4.5.2. Prevalent cases of CKD by stage in Spain

6.4.5.3. Prevalent cases of CKD by etiologies in Spain

6.4.5.4. Comorbidities associated with CKD in Spain

6.4.5.5. Dialysis Dependency in CKD in Spain

6.4.6. The United Kingdom

6.4.6.1. Diagnosed Prevalent cases of CKD in the United Kingdom

6.4.6.2. Prevalent cases of CKD by stage in the United Kingdom

6.4.6.3. Prevalent cases of CKD by etiologies in the United Kingdom

6.4.6.4. Comorbidities associated with CKD in the United Kingdom

6.4.6.5. Dialysis Dependency in CKD in the United Kingdom

6.5. Japan

6.5.1. Assumption and Rationale

6.5.2. Diagnosed Prevalent cases of CKD in Japan

6.5.3. Prevalent cases of CKD by stage in Japan

6.5.4. Prevalent cases of CKD by etiologies in Japan

6.5.5. Comorbidities associated with CKD in Japan

6.5.6. Dialysis Dependency in CKD in Japan

7. Treatment and Management

7.1. Biosimilars

7.2. Treatment guidelines for CKD

7.2.1. Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline

7.2.2. NICE Guidelines

7.3. Case Study

7.3.1. Improving Outcomes for Patients with Chronic Kidney Disease

7.4. Patient Journey for CKD

8. Unmet Needs

9. Marketed Products

9.1. Epogen (Epoetin alfa): Amgen

9.1.1. Product Description

9.1.2. Product Developmental Activity

9.1.3. Safety and Efficacy

9.2. Aranesp (Darbepoetin alfa): Amgen

9.2.1. Product Description

9.2.2. Product Developmental Activity

9.2.3. Safety and Efficacy

9.3. Feraheme: Amag Pharmaceuticals

9.3.1. Product Description

9.3.2. Product Developmental Activity

9.3.3. Safety and Efficacy

9.4. Parsabiv (etelcalcetide): Amgen

9.4.1. Product Description

9.4.2. Product Developmental Activity

9.4.3. Safety and Efficacy

9.5. Sensipar (Cinacalcet): Amgen

9.5.1. Product Description

9.5.2. Product Developmental Activity

9.5.3. Safety and Efficacy

9.6. Auryxia: Keryx Biopharmaceuticals

9.6.1. Product Description

9.6.2. Product Developmental Activity

9.6.3. Safety and Efficacy

9.7. Paricalcitol (Zemplar): AbbVie

9.7.1. Product Description

9.7.2. Product Developmental Activity

9.7.3. Safety and Efficacy

9.8. Velphoro(Sucroferric oxyhydroxide): Vifor Pharma

9.8.1. Product Description

9.8.2. Product Developmental Activity

9.8.3. Safety and Efficacy

9.9. Rayaldee (CTAP101): OPKO IP Holdings II, Inc.|OPKO Health, Inc.

9.9.1. Drug Description

9.9.2. Other Developmental Activities

9.9.3. Clinical Development

9.9.3.1. Clinical Trials Information

9.9.4. Safety and Efficacy

9.10. CKD-11101: Chong Kun Dang Pharmaceuticals

9.10.1. Product Description

9.10.2. Other Developmental Activities

9.10.3. Clinical Development

9.10.3.1. Clinical trials information

9.10.4. Safety and Efficacy

10. Emerging Therapies

10.1. Daprodustat: GlaxoSmithKline

10.1.1. Drug Description

10.1.2. Other Developmental Activities

10.1.3. Clinical Development

10.1.3.1. Clinical trials information

10.1.4. Safety and Efficacy

10.2. Vadadustat: Akebia Therapeutics

10.2.1. Drug Description

10.2.2. Other Developmental Activities

10.2.3. Clinical Development

10.2.3.1. Clinical trials information

10.2.4. Safety and Efficacy

10.3. Roxadustat: FibroGen/Astellas Pharma/ AstraZeneca

10.3.1. Drug Description

10.3.2. Other Developmental Activities

10.3.3. Clinical Development

10.3.3.1. Clinical trials information

10.3.4. Safety and Efficacy

10.4. Empagliflozin: Boehringer Ingelheim

10.4.1. Drug Description

10.4.2. Other Developmental Activities

10.4.3. Clinical Development

10.4.3.1. Clinical trials information

10.4.4. Safety and Efficacy

10.5. Veverimer: Tricida

10.5.1. Drug Description

10.5.2. Other Developmental Activities

10.5.3. Clinical Development

10.5.3.1. Clinical trials information

10.5.4. Safety and Efficacy

10.6. Dapagliflozin: AstraZeneca

10.6.1. Drug Description

10.6.2. Other Developmental Activities

10.6.3. Clinical Development

10.6.3.1. Clinical trials information

10.6.4. Safety and Efficacy

10.7. Ziltivekimab: Corvidia Therapeutics

10.7.1. Product Description

10.7.2. Clinical Development

10.7.2.1. Clinical Trials Information

10.7.3. Safety and Efficacy

10.8. Bardoxolone methyl: Reata Pharmaceuticals.

10.8.1. Drug Description

10.8.2. Other Developmental Activities

10.8.3. Clinical Development

10.8.4. Safety and Efficacy

11. CKD: 7 Major Market Analysis

11.1. Key Findings

11.2. Total Market Size of CKD in 7MM

12. Market Outlook: 7 MM

13. Country-wise Market Size

14. United States

14.1. Total Market size of CKD

14.2. CKD Market Size by Therapies (Dialysis Dependent)

14.3. CKD Market Size by Therapies (Non-Dialysis Dependent)

15. EU5 Countries

15.1. Germany

15.1.1. Total Market size of CKD

15.1.2. CKD Market Size by Therapies (DD)

15.1.3. CKD Market Size by Therapies (NDD)

15.2. France

15.2.1. Total Market size of CKD

15.2.2. CKD Market Size by Therapies (DD)

15.2.3. CKD Market Size by Therapies

15.3. Italy

15.3.1. Total Market size of CKD

15.3.2. CKD Market Size by Therapies (DD)

15.3.3. CKD Market Size by Therapies

15.4. Spain

15.4.1. Total Market size of CKD

15.4.2. CKD Market Size by Therapies (DD)

15.4.3. CKD Market Size by Therapies (NDD)

15.5. United Kingdom

15.5.1. Total Market size of CKD

15.5.2. CKD Market Size by Therapies (DD)

15.5.3. CKD Market Size by Therapies (NDD)

16. Japan

16.1. Total Market size of CKD

16.2. CKD Market Size by Therapies (DD)

16.3. CKD Market Size by Therapies (NDD)

17. Market Access and Reimbursement

19. Market Drivers

20. Market Barriers

21. Appendix

21.1. Report Methodology

22. DelveInsight Capabilities

23. Disclaimer

24. About DelveInsight

Table 1: Summary of Chronic Kidney Disease (CKD) Market, Epidemiology, and Key Events (2017–2030)

Table 2: Total Prevalent Patient Population of CKD in 7MM (2017–2030)

Table 3: Diagnosed Prevalent Cases of CKD in the United States (2017-2030)

Table 4: Prevalent Cases of CKD by stage in the United States (2017-2030)

Table 5: Prevalent cases of CKD by etiologies in the United States (2017-2030)

Table 6: Comorbidities associated with CKD in the United States (2017-2030)

Table 7: Dialysis dependency in the United States (2017-2030)

Table 8: Diagnosed Prevalent Cases of CKD in Germany (2017-2030)

Table 9: Prevalent Cases of CKD by stage in Germany (2017-2030)

Table 10: Prevalent cases of CKD by etiologies in Germany (2017-2030)

Table 11: Comorbidities associated with CKD in Germany (2017-2030)

Table 12: Dialysis dependency in Germany (2017-2030)

Table 13: Diagnosed Prevalent Cases of CKD in France (2017-2030)

Table 14: Prevalent Cases of CKD by stage in France (2017-2030)

Table 15: Prevalent cases of CKD by etiologies in France (2017-2030)

Table 16: Comorbidities associated with CKD in France (2017-2030)

Table 17: Dialysis dependency in France (2017-2030)

Table 18: Diagnosed Prevalent Cases of CKD in Italy (2017-2030)

Table 19: Prevalent Cases of CKD by stage in Italy (2017-2030)

Table 20: Prevalent cases of CKD by etiologies in Italy (2017-2030)

Table 21: Comorbidities associated with CKD in Italy (2017-2030)

Table 22: Dialysis dependency in Italy (2017-2030)

Table 23: Diagnosed Prevalent Cases of CKD in Spain (2017-2030)

Table 24: Prevalent Cases of CKD by stage in Spain (2017-2030)

Table 25: Prevalent cases of CKD by etiologies in Spain (2017-2030)

Table 26: Comorbidities associated with CKD in Spain (2017-2030)

Table 27: Dialysis dependency in Spain (2017-2030)

Table 28: Diagnosed Prevalent Cases of CKD in the United Kingdom (2017-2030)

Table 29: Prevalent Cases of CKD by stage in the United Kingdom (2017-2030)

Table 30: Prevalent cases of CKD by etiologies in the United Kingdom (2017-2030)

Table 31: Comorbidities associated with CKD in the United Kingdom (2017-2030)

Table 32: Dialysis dependency in the United Kingdom (2017-2030)

Table 33: Diagnosed Prevalent Cases of CKD in Japan (2017-2030)

Table 34: Prevalent Cases of CKD by stage in Japan (2017-2030)

Table 35: Prevalent cases of CKD by etiologies in Japan (2017-2030)

Table 36: Comobidities associated with CKD in Japan (2017-2030)

Table 37: Dialysis dependency in Japan (2017-2030)

Table 38: Summary of ESAs:

Table 39: CTAP101, Clinical Trial Description, 2020

Table 40: CKD-1101, Clinical Trial Description, 2020

Table 41:Daprodustat, Clinical Trial Description, 2020

Table 42: Vadadustat, Clinical Trial Description, 2020

Table 43:Roxadustat, Clinical Trial Description, 2020

Table 44:Empagliflozin, Clinical Trial Description, 2020

Table 45:Veverimer, Clinical Trial Description, 2020

Table 46: Dapagliflozin, Clinical Trial Description, 2020

Table 47:Ziltivekimab, Clinical Trial Description, 2020

Table 48:Bardoxolone methyl, Clinical Trial Description 2020

Table 49: 7 Major Market Size of CKD in USD Million (2017–2030)

Table 50: The US Market size of CKD in USD Million (2017–2030)

Table 51: The US market size of CKD by Therapies (DD) in USD Million (2017–2030)

Table 52: The US market size of CKD by Therapies (NDD) in USD Million (2017–2030)

Table 53: Germany Market size of CKD in USD Million (2017–2030)

Table 54: Germany market size of CKD by Therapies (DD) in USD Million (2017–2030)

Table 55: Germany market size of CKD by Therapies (NDD) in USD Million (2017–2030)

Table 56: France Market size of CKD in USD Million (2017–2030)

Table 57: France market size of CKD by Therapies (DD) in USD Million (2017–2030)

Table 58: France market size of CKD by Therapies (NDD) in USD Million (2017–2030)

Table 59: Italy Market size of CKD in USD Million (2017–2030)

Table 60: Italy market size of CKD by Therapies (DD) in USD Million (2017–2030)

Table 61: Italy market size of CKD by Therapies (NDD) in USD Million (2017–2030)

Table 62: Spain Market size of CKD in USD Million (2017–2030)

Table 63: Spain market size of CKD by Therapies (DD) in USD Million (2017–2030)

Table 64: Spain market size of CKD by Therapies (NDD) in USD Million (2017–2030)

Table 65: The CKD Market size of CKD in USD Million (2017–2030)

Table 66: The UK market size of CKD by Therapies (DD) in USD Million (2017–2030)

Table 67: The UK market size of CKD by Therapies (NDD) in USD Million (2017–2030)

Table 68: Japan Market size of CKD in USD Million (2017–2030)

Table 69: Japan market size of CKD by Therapies (DD) in USD Million (2017–2030)

Table 70: Japan market size of CKD by Therapies (NDD) in USD Million (2017–2030)

Figure 1: SWOT Analysis

Figure 2: Total Prevalent Patient Population of CKD in 7MM (2017–2030)

Figure 3:  Diagnosed prevalent cases of CKD in the United States (2017-2030)

Figure 4: Prevalent Cases of CKD by stage in the United States (2017-2030)

Figure 5: Prevalent cases of CKD by etiologies in the United States (2017-2030)

Figure 6: Comorbidities associated with CKD in the United States (2017-2030)

Figure 7: Dialysis dependency in the United States (2017-2030)

Figure 8:  Diagnosed prevalent cases of CKD in Germany (2017-2030)

Figure 9: Prevalent Cases of CKD by stage in Germany (2017-2030)

Figure 10: Prevalent cases of CKD by etiologies in the Germany (2017-203

Figure 11: Comorbidities associated with CKD Germany (2017-2030)

Figure 12: Dialysis dependency in Germany (2017-2030)

Figure 13:  Diagnosed prevalent cases of CKD in the France (2017-2030)

Figure 14: Prevalent Cases of CKD by stage in France (2017-2030)

Figure15: Prevalent cases of CKD by etiologies in France (2017-2030)

Figure 16: Comorbidities associated with CKD in France (2017-2030)

Figure 17: Dialysis dependency in France (2017-2030)

Figure 18:  Diagnosed prevalent cases of CKD in Italy (2017-2030)

Figure 19: Prevalent Cases of CKD by stage in Italy (2017-2030)

Figure 20: Prevalent cases of CKD by etiologies in Italy (2017-2030)

Figure 21: Comorbidities associated with CKD in Italy (2017-2030)

Figure 22: Dialysis dependency in Italy (2017-2030)

Figure 23:  Diagnosed prevalent cases of CKD in Spain (2017-2030)

Figure 24: Prevalent Cases of CKD by stage in Spain (2017-2030)

Figure 25: Prevalent cases of CKD by etiologies in Spain (2017-2030)

Figure 26: Comorbidities associated with CKD in Spain (2017-2030)

Figure 27: Dialysis dependency in Spain (2017-2030)

Figure 28:  Diagnosed prevalent cases of CKD in the United Kingdom (2017-2030)

Figure 29: Prevalent Cases of CKD by stage in the United Kingdom (2017-2030)

Figure 30: Prevalent cases of CKD by etiologies in the United Kingdom (2017-2030)

Figure 31: Comorbidities associated with CKD in the United Kingdom(2017-2030)

Figure 32: Dialysis dependency in the United Kingdom (2017-2030)

Figure 33:  Diagnosed prevalent cases of CKD in Japan (2017-2030)

Figure 34: Prevalent Cases of CKD by stage in Japan (2017-2030)

Figure 35: Prevalent cases of CKD by etiologies in Japan (2017-2030)

Figure 36: Comorbidities associated with CKD in Japan (2017-2030)

Figure 37: Dialysis dependency in the Japan (2017-2030)

Figure 38: Steps in Manufacturing a Biologic Drug

Figure 39: Unmet Needs of Chronic Kidney Disease (CKD)

Figure 40: 7 Major Market Size of CKD in USD Million (2017–2030)

Figure 41: Market Size of CKD in the United States, USD Millions (2017–2030)

Figure 42: The U.S. market size of CKD by therapies (DD) in USD Million (2017–2030)

Figure 43: The U.S. market size of CKD by therapies (NDD) in USD Million (2017–2030)

Figure 44: Market Size of CKD in Germany, USD Millions (2017–2030)

Figure 45: Germany market size of CKD by therapies (DD) in USD Million (2017–2030)

Figure 46: Germany market size of CKD by therapies (NDD) in USD Million (2017–2030)

Figure 47: Market Size of CKD in France, USD Millions (2017–2030)

Figure 48: France market size of CKD by therapies (DD) in USD Million (2017–2030)

Figure 49: France market size of CKD by therapies (NDD) in USD Million (2017–2030)

Figure 50: Market Size of CKD in Italy, USD Millions (2017–2030)

Figure 51: Italy market size of CKD by therapies (DD) in USD Million (2017–2030)

Figure 52: Italy market size of CKD by therapies (NDD) in USD Million (2017–2030)

Figure 53: Market Size of CKD in Spain, USD Millions (2017–2030)

Figure 54: Spain market size of CKD by therapies (DD) in USD Million (2017–2030)

Figure 55: Spain market size of CKD by therapies (NDD) in USD Million (2017–2030)

Figure 56: Market Size of CKD in the UK, USD Millions (2017–2030

Figure 57: The UK market size of CKD by therapies (DD) in USD Million (2017–2030)

Figure 58: The UK market size of CKD by therapies (NDD) in USD Million (2017–2030)

Figure 59: Market Size of CKD in Japan, USD Millions (2017–2030)

Figure 60: Japan market size of CKD by therapies (DD) in USD Million (2017–2030)

Figure 61: Japan market size of CKD by therapies (NDD) in USD Million (2017–2030)

Figure 62: Key Takeaways for Market Access and Reimbursement of CKD Treatment

Figure 63: Market Drivers

Figure 64: Market Barriers

  • Tags:
  • Chronic Kidney Disease (Chronic Ren...
  • Chronic Kidney Disease (Chronic Ren...
  • Chronic Kidney Disease (Chronic Ren...
  • Chronic Kidney Disease (Chronic Ren...
  • Chronic Kidney Disease (Chronic Ren...
  • Chronic Kidney Disease (Chronic Ren...
  • Chronic Kidney Disease (Chronic Ren...
  • Chronic Kidney Disease (Chronic Ren...
  • Chronic Kidney Disease (Chronic Ren...
  • Chronic Kidney Disease (Chronic Ren...
  • Chronic Kidney Disease (Chronic Ren...
  • Chronic Kidney Disease (Chronic Ren...
  • Chronic Kidney Disease (Chronic Ren...
  • Chronic Kidney Disease (Chronic Ren...

Forward to Friend

Need A Quote